| CAS NO: | 35807-85-3 |
| 包装 | 价格(元) |
| 10mM (in 1mL DMSO) | 电议 |
| 100mg | 电议 |
| 500mg | 电议 |
| Physical Appearance | A solid |
| Storage | Store at -20°C |
| M.Wt | 521.69 |
| Cas No. | 35807-85-3 |
| Formula | C26H44NNaO6S |
| Solubility | ≥26.1 mg/mL in DMSO; ≥2.61 mg/mL in EtOH with gentle warming and ultrasonic; ≥8.42 mg/mL in H2O |
| Chemical Name | sodium (R,Z)-4-((3R,5S,7S,8R,9S,10S,13R,14S,17R)-3,7-dihydroxy-10,13-dimethylhexadecahydro-1H-cyclopenta[a]phenanthren-17-yl)-N-(2-sulfoethyl)pentanimidate |
| Canonical SMILES | C[C@]([C@@]1([H])CC[C@@]2([H])[C@@]([C@](O)([H])C[C@]3([H])C[C@@](O)([H])CC[C@@]34C)([H])[C@]4([H])CC[C@]12C)([H])CC/C([O-])=N/CCS(O)(=O)=O.[Na+] |
| 运输条件 | 蓝冰运输或根据您的需求运输。 |
| 一般建议 | 为了使其更好的溶解，请用37℃加热试管并在超声波水浴中震动片刻。不同厂家不同批次产品溶解度各有差异，仅做参考。若实验所需浓度过大至产品溶解极限，请添加助溶剂助溶或自行调整浓度。溶液形式一般不宜长期储存，请尽快用完。 |
Sodium tauroursodeoxycholate (TUDC) 对胆汁淤积具有治疗效果[1,2]。在人红细胞中，它抑制胆汁盐诱导的2’,7’-bis-(carboxypropyl)-5(6)-carboxyfluorescein (BCPCF)外流，IC50值为560 μM [3]。
胆汁淤积是胆汁生成障碍所引起的病症，胆汁生成具有重要作用[4]。
cVA-of-CLF意味着 cholyllysylfluorescein的小管空泡累积[1]。CLF的cVA是总胆汁分泌参数[5]。用17βEG培养会剂量依赖性的减少细胞的cVA-of-CLF。50 μM浓度的17βEG使cVA-of-CLF下降40％。同时用TUDC和17βEG培养将cVA 的下降改善24％。同时用SAMe和17βEG培养将cVA 的下降改善18％。与TUDC相比，同时用TUDC、17βEG和SAMe培养将cVA 的下降改善28％。但是TUDC和SAMe的共同效果并不比任何保护剂的单独效果显著[1]。
在大鼠中，腹腔给药500 μg/kg的毒伞素7天，引起肝内胆汁淤积。在这些给药大鼠中，胆汁流量减少，谷丙转氨酶、亮氨酸氨肽酶、血清碱性磷酸酶的活性以及胆汁酸、磷脂和胆固醇的浓度升高。但是，tauroursodeoxycholate显著抑制这些效应。在这些大鼠中，tauroursodeoxycholate显著地改善了胆汁胆固醇和磷脂的排泄率[2]。
参考文献：
[1]. Milkiewicz P, Roma MG, Cardenas R, et al. Effect of tauroursodeoxycholate and S-adenosyl-l-methionine on 17β-estradiol glucuronide-induced cholestasis. Journal of hepatology, 2001, 34(2): 184-191.
[2]. Ishizaki K, Kinbara S, Hirabayashi N, et al. Effect of sodium tauroursodeoxycholate on phalloidin-induced cholestasis in rats. European journal of pharmacology, 2001, 421(1): 55-60.
[3]. Mrowczynska L, Bobrowska-Hgerstrand M, Wrobel A, et al. Inhibition of MRP1-mediated efflux in human erythrocytes by mono-anionic bile salts. Anticancer research, 2005, 25(5): 3173-3178.
[4]. Trauner M, Meier PJ, Boyer JL. Molecular pathogenesis of cholestasis. New England Journal of Medicine, 1998, 339(17): 1217-1227.
[5]. Milkiewicz P, Roma MG, Elias E, et al. Hepatoprotection with tauroursodeoxycholate and β muricholate against taurolithocholate induced cholestasis: involvement of signal transduction pathways. Gut, 2002, 51(1): 113-119.
m.cnreagent.com